Thanks, Daniel, and good morning, everyone. Before we get to our prepared remarks, I'm sure all of you are wondering why Rob isn't with us. Unfortunately, he caught the flu bug that's been going around the country and won't be with us today. I'm quite sure he's listening, however, and he's gonna be critiquing our performance. So Matt and I are gonna do our best to get through this call and hopefully get a good review from him when we talk to him later. With that, I'll turn back to our prepared remarks. Fiscal 2025 is off to a good start. Our strong Q1 financial results were driven by cost management and benefits we continue to see from our diversified portfolio. These results were delivered as we successfully executed major ERP conversions at PCB, PET, and Weetabix during the quarter. Given the potential pitfalls involved with these types of projects, the performance of our teams was commendable, and we are grateful for their efforts. At PCD, Pet and Grocery had a strong quarter with improved gross margin in both, driven by cost performance. For grocery, we benefited from improved utilization due to our plant closure completed last September, as well as freight efficiencies. For Pet, we benefited from improved cost and plant performance. From a volume standpoint, the cereal category declined 3.2%, slightly more than our planned assumptions. PCB's pound share remained flat at 22% with solid performance across the portfolio. Meanwhile, pet category consumption was down approximately 1% with our portfolio declining 5% as we continued to lap lost distribution points in Nutrish and experience price elasticity in Gravy Train. Our overall share was down slightly. We are now turning our attention to innovation for Pet in Q2, led by the relaunch of Nutrish, which is underway now with phasing throughout the balance of the fiscal year. In addition, we are rolling out innovation with new product launches in Nature's Recipe and Kibbles and Bits. Shifting to foodservice, overall, we had a strong quarter driven by continued volume growth, ongoing avian influenza pricing from the May 2024 outbreak, and improved supply chain performance. While restaurant foot traffic remained soft, we saw some year-over-year stabilization. Nevertheless, we continue to grow our volumes in both egg and potato products with our higher value-added eggs leading the way at plus 5%. The quarter ended on a challenging note as two of our third-party contracted farms were hit with Avian Influenza in December. While this did not have a material impact on Q1, when combined with the significant additional avian influenza outbreaks across the industry, our supply imbalance will cause sourcing and cost challenges, especially in our fiscal Q2. We have successfully priced through each avian influenza outbreak in the past. And while the magnitude of current market prices and volatility are unprecedented, we are confident in our ability to navigate through the current landscape. We estimate the cost before pricing impact on our fiscal second quarter will be a headwind in the range of $30 million to $50 million when compared to the fiscal first quarter results. Given the volatility in ag market prices, the actual result could vary perhaps significantly from this range. Importantly, however, we remain confident in our ability to recover any second-quarter cost before pricing impact in the balance of the fiscal year. Please note this assumes we recover our lost egg supply as planned and see no additional avian influenza outbreaks within our controlled farms. Turning to refrigerated retail, Q1 adjusted EBITDA was down significantly to prior year. Roughly half of this decline was expected as last year benefited from customer-sponsored promotion that did not repeat this year. In addition, shelf reset relocations at a major customer created a temporary weakness in our side offerings. Finally, we experienced cost ahead of pricing for both sausage and eggs. Our focus in the balance of the year for this segment is to continue driving growth in our sides business while we maintain cost discipline. At Weetabix, business performance was down as expected as we pulled back on promotions while we worked through our ERP conversion. From a volume perspective, the cereal category was down 1.6% with declines in both branded and private label. However, a bright spot was our core Weetabix product, which was up 3.6%. With the ERP conversion behind us, our focus shifts to ramping marketing to drive volume growth while we continue to execute our identified cost-out opportunities. Before turning the call over to Matt, I want to make a few comments on the macro consumer environment and capital allocation. The macro environment remained challenging with continued pressure on the consumer and therefore collective volumes across our sector. Adding to this, the new administration and its potential policies have driven uncertainty across the consumer landscape. We continue to see an active pipeline of potential M&A transactions both large and small. Since the beginning of the fiscal year, our capital allocation has focused on share repurchase as we bought back over 4% of our shares while keeping our net leverage flat. Given our strong liquidity and cash flow, we continue to be well-positioned to take advantage of the opportunities and we remain disciplined as we evaluate the optimal allocation of your capital. With that, I'll turn the call over to Matt.